Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

COVID-19 EUA Testing Requirement Change

the U.S. Food & Drug Administration Center for Drug Evaluation & Research  |  March 17, 2023

On Feb. 3, the U.S. Food & Drug Administration (FDA) revised its Letters of Authorization for two emergency use authorizations (EUAs), Paxlovid and Lagevrio, to remove the requirement for positive test results to prescribe these drugs. The agency continues to recommend that providers use direct SARS-CoV-2 viral testing to help diagnose COVID-19. The FDA recognizes…

Filed under:Drug Updates Tagged with:COVID-19FDASARS-CoV-2

What We Know about COVID-19 in 2023: Variants, Vaccines, New Therapies & More

Ruth Jessen Hickman, MD  |  March 16, 2023

Although a less central focus than it was three years ago, rheumatologists must still consider the prevention and management of SARS-CoV-2 in their patients. The following update shares ongoing considerations related to the COVID-19 pandemic. Outcomes At the beginning of the pandemic, it was unclear whether patients with rheumatic disease would be at higher risk…

Filed under:Conditions Tagged with:COVID-19SARS-CoV-2

Long COVID: Experts Weigh in on Increasingly Common Syndrome

Ruth Jessen Hickman, MD  |  March 16, 2023

A minority of patients experience lingering symptoms after infec­tion with SARS-CoV-2, similar to some other previously known post-infection syndromes. Although we are just beginning to understand the differ­ent presen­tations, pathophysiology, risk factors, prognosis and treatment of long COVID, rheumatologists can play a leader­ship role in managing patients with the illness and contributing to this important research…

Filed under:ConditionsResearch Rheum Tagged with:COVID-19SARS-CoV-2

FDA Approves Sarilumab for the Treatment of Adults with Glucocorticoid-Resistant PMR

Michele B. Kaufman, PharmD, BCGP  |  March 14, 2023

Sarilumab is now FDA approved to treat adults with polymyalgia rheumatica who have had an inadequate response to glucocorticoids or who cannot tolerate a glucocorticoid taper. This new indication is based on results from the multicenter, phase 3 SAPHYR trial.

Filed under:Drug Updates Tagged with:FDA approvalglucocorticoidPolymyalgia RheumaticasarilumabU.S. Food and Drug Administration (FDA)

Conflicts of Interest in Guideline Development: What to Do When Everyone Has a Conflict

Anne R. Bass, MD  |  March 12, 2023

Avoiding real and apparent conflicts of interest is a fundamental principle of guideline development, but what should we do when every thought leader is conflicted? An example of this conundrum in rheumatology has been the ACR’s ongoing effort to establish guidelines for the management of lupus nephritis, which has been stymied by the fact that…

Filed under:Clinical Criteria/GuidelinesEthicsProfessional Topics Tagged with:Conflict of interest

ACR Image Competition 2022, Part 4

Joana Martins Martinho, MD  |  March 12, 2023

Periungual Erythema & Its Translation on Nailfold Videocapillaroscopy in a Patient with Very Early Systemic Sclerosis A 66-year-old woman presented with Raynaud’s phenomenon and periungual erythema. HEp-2 immunofluorescence assay was positive for antinuclear antibodies, showing a centromere pattern. The presence of anti-centromere antibodies was confirmed by chemiluminescent immunoassay. The patient was diagnosed with very early…

Filed under:ConditionsSystemic Sclerosis Tagged with:Image CompetitionRaynaud'ssclerosis

Case Report: Is It Cardiac Sarcoidosis or COVID-19 Myocarditis?

Simranjit Kaur, MBBS, Sirajum Munira, MD, Farooq H. Sheikh, MD, FACC, & Anjani Pillarisetty, MD, RhMSUS  |  March 12, 2023

COVID-19 causes myriad cardiac dysfunctions, ranging from mild to fulminant disease, including myocarditis, acute congestive heart failure, cardiogenic shock and sudden cardiac death.1,2 COVID-19 myocarditis can mimic cardiac sarcoidosis clinically and on cardiac imaging, which can lead to diagnostic challenges and treatment delays. We present a case of cardiac sarcoidosis with interval development of metabolic…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:case reportCOVID-19myocarditispulmonary sarcoidosisSarcoidosis

Speak Out Rheum: Musings on Our Past & Rheumatology

David R. Mandel, MD, FACR  |  March 10, 2023

I have been reading Yuval Harari’s thought-provoking and engaging book, Sapiens: A Brief History of Humankind, about our species’ struggles and the path that led to our emergence as the predominant species. I was captivated by the drawing of the hand of one of our ancestors and mused about what that forebear was thinking as…

Filed under:OpinionSpeak Out Rheum Tagged with:HistorySpeak Out Rheumatology

Glucocorticoid Use May Result in Loss of Bone Mineral Density

Michele B. Kaufman, PharmD, BCGP  |  March 8, 2023

Adami et al. examined the fracture risk associated with glucocorticoid treatment in women with inflammatory rheumatic musculoskeletal diseases, finding that low-dose glucocorticoid use may result in significant bone mineral density loss in patients who are not on anti-osteoporotic drugs.

Filed under:ACR ConvergenceDrug Updates Tagged with:ACR Convergence 2022bone lossbone mineral density (BMD)fracture riskGlucocorticoidsinflammatory musculoskeletal disease

ACR Releases New Vaccination Guideline

Ruth Jessen Hickman, MD  |  March 6, 2023

The ACR recently released its first guideline focused on vaccination in adult and pediatric patients with rheumatic and musculoskeletal diseases.1 The guideline recommends modifications to certain vaccine and medication schedules to increase immunogenicity and ensure patient safety, while encouraging providers not to miss vaccination opportunities. The Need Patients with rheumatic conditions who are on immunosuppressive…

Filed under:Clinical Criteria/GuidelinesConditionsDrug Updates Tagged with:pneumococcal vaccinerecommendationsrheumatic and musculoskeletal diseasesRMDseasonal influenza vaccinationvaccinationvaccinesvaricella zoster vaccine

  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 323
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences